Drug Trial Radar · NCT01957735
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Feb 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
97
Actual
Start
Oct 2013
Primary completion
Feb 1, 2017
Study completion Feb 1, 2017
Sponsor
- Lead sponsor
- BPGbioIndustry
- Sponsor type
- Industry
- First posted
- Oct 8, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1a/b multicenter, open-label, non-randomized, dose-escalation study to examine the dose limiting toxicities (DLT) of BPM31510 administered as a 144-hour continuous intravenous (IV) infusion as monotherapy(treatment Arm 1) and in combination with chemotherapy (treatment Arm 2) in patients with solid tumors.
Conditions
- Metastatic Cancer
- Cancer
- Solid Tumor
Interventions
BP31510 monotherapyDrug
BP31510 in combination with chemotherapyDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine Maximum Tolerated Dose (MTD) of BP31510Time frame: Wach week of treatment for the duration of Cycle 1 up to 4 weeks on Arm 1 and 6 weeks for Arm 2
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Palo Alto Medical Foundation
Sunnyvale, California
Weill Cornell Solid Tumor Oncology Practice
New York, New York
The University of Texas MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.